Comparing cisplatin-Chemoradiotherapy to Cetuximab-radiotherapy in HPV(+) “low-risk” locally advanced oropharyngeal squamous cell carcinoma: lessons from De-escalate study

Lignende værker

• Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial
  af: Jones, David A., et al.
  Udgivet: (2020)
• Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin
  af: Swiecicki, Paul L., et al.
  Udgivet: (2020)
• Comparison of high-dose Cisplatin-based chemoradiotherapy and Cetuximab-based bioradiotherapy for p16-positive oropharyngeal squamous cell carcinoma in the context of revised HPV-based staging
  af: Bhattasali, Onita, et al.
  Udgivet: (2018)
• Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial
  af: Mehanna, Hisham, et al.
  Udgivet: (2019)
• Feasibility of Induction Docetaxel, Cisplatin, 5-Fluorouracil, Cetuximab (TPF-C) Followed by Concurrent Cetuximab Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma
  af: Charalambakis, Nikolaos, et al.
  Udgivet: (2013)